EP1263775A4 - Hla bindende peptide und ihre verwendung - Google Patents

Hla bindende peptide und ihre verwendung

Info

Publication number
EP1263775A4
EP1263775A4 EP00910314A EP00910314A EP1263775A4 EP 1263775 A4 EP1263775 A4 EP 1263775A4 EP 00910314 A EP00910314 A EP 00910314A EP 00910314 A EP00910314 A EP 00910314A EP 1263775 A4 EP1263775 A4 EP 1263775A4
Authority
EP
European Patent Office
Prior art keywords
binding peptides
hla binding
hla
peptides
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00910314A
Other languages
English (en)
French (fr)
Other versions
EP1263775A1 (de
Inventor
Alessandro Sette
John Sidney
W Martin Kast
Scott Southwood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epimmune Inc
Original Assignee
Epimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epimmune Inc filed Critical Epimmune Inc
Publication of EP1263775A1 publication Critical patent/EP1263775A1/de
Publication of EP1263775A4 publication Critical patent/EP1263775A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP00910314A 2000-02-23 2000-02-23 Hla bindende peptide und ihre verwendung Withdrawn EP1263775A4 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2000/004655 WO2001062776A1 (en) 2000-02-23 2000-02-23 Hla binding peptides and their uses

Publications (2)

Publication Number Publication Date
EP1263775A1 EP1263775A1 (de) 2002-12-11
EP1263775A4 true EP1263775A4 (de) 2004-10-06

Family

ID=21741082

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00910314A Withdrawn EP1263775A4 (de) 2000-02-23 2000-02-23 Hla bindende peptide und ihre verwendung

Country Status (8)

Country Link
EP (1) EP1263775A4 (de)
JP (1) JP2003524016A (de)
CN (1) CN1452634A (de)
AU (1) AU2000232427A1 (de)
BR (1) BR0017136A (de)
CA (1) CA2400215A1 (de)
MX (1) MXPA02008219A (de)
WO (1) WO2001062776A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000225A1 (en) * 1999-06-29 2001-01-04 Epimmune Inc. Hla binding peptides and their uses
WO2001074845A2 (en) * 2000-03-31 2001-10-11 Aventis Pasteur Limited Immunogenic peptides derived from prostate-specific membrane antigen (psma) and uses thereof
US20030113919A1 (en) * 2001-08-17 2003-06-19 Aventis Pasteur, Ltd. Immunogenic targets for melanoma
WO2006009920A2 (en) 2004-06-17 2006-01-26 Mannkind Corporation Epitope analogs
EP1842911A4 (de) * 2005-01-25 2008-12-10 Nec Corp Hla bindende peptide, für diese codierende dna-fragmente und rekombinante vektoren
EP2371852A3 (de) 2005-06-17 2012-08-01 Mannkind Corporation Epitopanaloge
SG162817A1 (en) * 2005-06-17 2010-07-29 Mannkind Corp Methods and compositions.to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
CN1948333B (zh) * 2005-10-14 2010-12-08 中国人民解放军第二军医大学 一种新的hPEBP4蛋白来源的HLA-A2限制性表位多肽及其应用
EP2066689A4 (de) * 2006-09-07 2010-04-28 Univ South Florida Hyd1-peptide als antikrebsmittel
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
JP5792630B2 (ja) 2009-01-28 2015-10-14 エピミューン，インコーポレイティド Ｐａｎ−ｄｒ結合ポリペプチドおよびその使用
EP2547693B1 (de) 2010-03-19 2015-03-11 H. Lee Moffitt Cancer Center & Research Institute Integrininteraktionshemmer zur krebsbehandlung
JP5930967B2 (ja) 2010-09-08 2016-06-08 学校法人 埼玉医科大学 Ｃ型肝炎ウイルスリポソームワクチン
WO2015048477A1 (en) 2013-09-27 2015-04-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. Cyclic peptide conjugates and methods of use
IL302345A (en) * 2016-10-07 2023-06-01 Enterome S A Immunogenic compounds for cancer treatment
CN117801069A (zh) 2016-10-07 2024-04-02 恩特罗姆公司 用于癌症疗法的免疫原性化合物
US11712465B2 (en) 2016-10-07 2023-08-01 Enterome S.A. Microbiota sequence variants of tumor-related antigenic epitopes
MX2019005685A (es) 2016-11-30 2019-09-04 Advaxis Inc Composiciones inmunogenicas contra mutaciones de cancer recurrentes y metodos de uso de las mismas.
WO2019094607A2 (en) * 2017-11-08 2019-05-16 Advaxis, Inc. Immunogenic heteroclitic peptides from cancer-associated proteins and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994020127A1 (en) * 1993-03-05 1994-09-15 Cytel Corporation Hla-a2.1 binding peptides and their uses
WO1997034621A1 (en) * 1996-03-21 1997-09-25 Cytel Corporation Hla-a2.1 binding peptides and their uses
WO1998004284A1 (en) * 1996-07-25 1998-02-05 The Johns Hopkins University Novel genes of kaposi's sarcoma associated herpesvirus

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783567A (en) * 1997-01-22 1998-07-21 Pangaea Pharmaceuticals, Inc. Microparticles for delivery of nucleic acid

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994020127A1 (en) * 1993-03-05 1994-09-15 Cytel Corporation Hla-a2.1 binding peptides and their uses
WO1997034621A1 (en) * 1996-03-21 1997-09-25 Cytel Corporation Hla-a2.1 binding peptides and their uses
WO1998004284A1 (en) * 1996-07-25 1998-02-05 The Johns Hopkins University Novel genes of kaposi's sarcoma associated herpesvirus

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
NAYERSINA R ET AL: "HLA A2 RESTRICTED CYTOTOXIC T LYMPHOCYTE RESPONSES TO MULTIPLE HEPATITIS B SURFACE ANTIGEN EPITOPES DURING HEPATITIS B VIRUS INFECTION", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 150, no. 10, 15 May 1993 (1993-05-15), pages 4659 - 4671, XP000609159, ISSN: 0022-1767 *
NIJMAN H W: "IDENTIFICATION OF PEPTIDE SEQUENCES THAT POTENTIALLY TRIGGER HLA-A2.1-RESTRICTED CYTOTOXIC T LYMPHOCYTES", EUROPEAN JOURNAL OF IMMUNOLOGY, WEINHEIM, DE, vol. 23, 1 June 1993 (1993-06-01), pages 1215 - 1219, XP000674255, ISSN: 0014-2980 *
See also references of WO0162776A1 *
SETTE A ET AL: "PEPTIDE BINDING TO THE MOST FREQUENT HLA-A CLASS I ALLELES MEASURED BY QUANTITATIVE MOLECULAR BINDING ASSAYS", MOLECULAR IMMUNOLOGY, ELMSFORD, NY, US, vol. 31, no. 11, 1994, pages 813 - 822, XP000603774, ISSN: 0161-5890 *

Also Published As

Publication number Publication date
MXPA02008219A (es) 2005-06-30
WO2001062776A1 (en) 2001-08-30
JP2003524016A (ja) 2003-08-12
EP1263775A1 (de) 2002-12-11
BR0017136A (pt) 2003-02-25
AU2000232427A1 (en) 2001-09-03
CN1452634A (zh) 2003-10-29
CA2400215A1 (en) 2001-08-30

Similar Documents

Publication Publication Date Title
EP1578432A4 (de) Hla-bindende peptide und deren anwendungen
EG23122A (en) Pyrrolcarboxamides and pyrrolcarbothioamides
AU2001288301A1 (en) Binding polypeptides and methods based thereon
EP0888120A4 (de) Hla-bindende peptide und verwendung derselben
EP1263775A4 (de) Hla bindende peptide und ihre verwendung
AU9667901A (en) Mycoattractants and mycopesticides
GB0014870D0 (en) Peptides
GB2359863B (en) Turbocharger
GB2362604B (en) Book cover and book binding system using the book cover
EP1414848A4 (de) Replikin-peptide und ihre verwendungszwecke
EP1419175A4 (de) Replikin-peptide und anwendungen
GB0029777D0 (en) Peptides
EP1343819A4 (de) Hla-a2.1- bindungspeptide und ihre verwendung
GB0026134D0 (en) Peptides and their use
GB2364273B (en) Book covering
EP1313505A4 (de) Hla bindende peptide und deren verwendungen(18.03.02)
EP1337543A4 (de) Streptavidin-bindende peptide und deren verwendung
GB0001825D0 (en) Peptides
GB0020952D0 (en) Genes and proteins and their uses
GB0007263D0 (en) Peptides
EP1071434A4 (de) Cnre bindungsfaktoren und deren verwendungen
GB0018148D0 (en) Peptides and their use
GB0026136D0 (en) Peptides and their use
GB0026135D0 (en) Peptides and their use
GB0019503D0 (en) Proteins and their uses

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020822

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20040819

17Q First examination report despatched

Effective date: 20070213

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070824